AstraZeneca Group plc Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (73)

Latest Posts

About This Stock More About This Stock
Astrazeneca Vs. Novavax: Which Vaccine Stock Is A Better Buy?
Article By: StockNews
Saturday, February 13, 2021 7:41 PM EST
While neither Astrazeneca or Novavax will have a first-mover advantage if and when their vaccines are eventually brought to market their late-stage clinical trial results of AZN and NVAX are said to show a lot of promise.
In this article: AZN, NVAX
Read
Oxford COVID Vaccine Authorized In The UK
Article By: The Conversation
Friday, January 1, 2021 4:32 AM EST
What is the significance of the Oxford vaccine now being available? The Conversation asked Michael Head, an expert in global health at the University of Southampton, some key questions about why its authorization is important.
In this article: AZN, PFE, MRNA
Read
Major COVID Vaccine Glitch Emerges: Most Europeans, Including Hospital Staff, Refuse To Take It
Article By: Tyler Durden
Monday, December 28, 2020 3:49 AM EST
Europe rolled out a huge COVID-19 vaccination drive Sunday to try to rein in the coronavirus pandemic but many Europeans are skeptical about the speed at which the vaccines have been tested and approved and reluctant to have the shot.
In this article: AZN, PFE, MRNA, BNTX
Read
AstraZeneca To Buy Rare-Disease Specialist Drugmaker Alexion For $39 Billion
Article By: Benzinga
Saturday, December 12, 2020 12:07 PM EST
AstraZeneca plc has announced it will buy Alexion Pharmaceuticals, Inc. for $39 billion. AstraZeneca and Alexion said this morning that their boards unanimously approved the deal. It is expected to close in the third quarter of 2021.
In this article: AZN, ALXN Also: PFE, BNTX
Read
AstraZeneca Vaccine Only 62% Effective; Impact On Elderly Unclear As More Data Needed
Article By: Tyler Durden
Tuesday, December 8, 2020 11:49 AM EST
Unlike Moderna and Pfizer, the AstraZeneca vaccine (which uses a different method) was found to be just 62% effective for all volunteers who received two doses. And the study didn't involve even a single volunteer above the age of 55.
In this article: AZN
Read

Latest Tweets for $AZN

No tweets yet!

$AZN

Astrazeneca Vs. Novavax: Which Vaccine Stock Is A Better Buy?
Karen Klein 2/14/2021 4:58:18 AM

$AZN looks like the best option since it's easy to transport and so cheap to produce. But it sounds like it's not particularly effective against the new strains.

VistaGen Is Prepared For 2021 Fueled By Recent Analyst Upgrades And Large Institutional Buyers
Terrence Howard 1/11/2021 6:59:49 AM

Good article, thanks. Totally unrelated but what do you think about $AZN? I know Pfizer and Moderna have the head start on the vaccine, but it sounds like AZN's drug will be almost as effective at 90% efficacy (if they can replicate their initial test where they accidentally gave a quarter of the participants a 1/2 dose). And at $2 per vial instead of $200, I would think it will be the drug of choice for populous, yet poor nations like India, and Africa. Plus there will be no need for specialized freezers.

AstraZeneca Vaccine Only 62% Effective; Impact On Elderly Unclear As More Data Needed
Craig Newman 12/8/2020 5:20:20 PM

$AZN has not even filed or talked about filing in US or UK to my knowledge. They are hoping to get India to bite first via Serum Institute. Their trial was so F'd UP the most value to FDA is in denying to prove that other approvals are REAL..

Market Briefing For Thursday, September 10
Adam Reynolds 11/29/2020 5:39:15 PM

What's your take on the latest news on $AZN?

Good Day For Bad News
Ayelet Wolf 11/29/2020 5:37:45 PM

I thought this as well. 90% efficacy is almost as good as the 95% efficacy of the #Pfizer and #Moderna vaccines. But is a much cheaper alternative. Bullish on $AZN

Market Briefing For Thursday, September 10
Atif Ozcelik 9/10/2020 10:37:10 AM

Comments on the major vaccine producers are very useful; thank for the information on $SRNE, $AZN.

When Profits and Politics Drive Science: Rushing a Vaccine to Market for a Vanishing Virus
Adam Reynolds 6/4/2020 5:09:08 PM

Yes and Fauci and other experts said corona is likely here to stay. We will probably have seasonal outbreaks every year. There will be plenty of time to profit from a vaccine. Bullish on $AZN, $MRNA.

1 to 7 of 7 comments